10 results
8-K
EX-99.2
MRNS
Marinus Pharmaceuticals Inc
9 Nov 21
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
7:03am
, median 7.0 5.0 6.0 Gender, n (%) Male 10 (19.6) 11 (22.0) 21 (20.8) Female 41 (80.4) 39 (78.0) 80 (79.2) Ethnicity, n (%) Hispanic or Latino 6 (11.8) 4 … (8.0) 10 (9.9) Not - Hispanic or Latino 43 (84.3) 44 (88.0) 87 (86.1) Unknown 1 (2.0) 1 (2.0) 2 (2.0) Not reported 1 (2.0) 1 (2.0) 2 (2.0) Race, n
8-K
EX-99.1
MRNS
Marinus Pharmaceuticals Inc
17 Aug 21
Other Events
4:13pm
) 11 (22.0) 21 (20.8) Female 41 (80.4) 39 (78.0) 80 (79.2) Ethnicity, n (%) Hispanic or Latino 6 (11.8) 4 (8.0) 10 (9.9) Not - Hispanic or Latino 43
8-K
EX-99.2
mfdnlfnq
10 Aug 21
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
7:16am
8-K
EX-99.2
qigxcf9p37u 9hlx
17 May 21
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
12:00am
8-K
EX-99.2
opytrfn8kq2m03w
9 Mar 21
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results
7:05am
8-K
EX-99.2
3m11a2
7 Dec 20
Other Events
8:03am
8-K
EX-99.2
74wxnem
14 Sep 20
Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy
5:17pm
- Prev
- 1
- Next